Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director comp.
LadRx Corp (CYTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K/A Quarterly results
05/11/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of LADRX Corporation",
"LadRx Announces Reverse Stock Split"
12/30/2022 8-K Quarterly results
09/23/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of CytRx CORPORATION CytRx Corporation , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on February 28, 1985. 2. The Restated Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on November 15, 2007 . 3. The Certificate of Incorporation was further amended by Certificates of Amendment of Restated Certificate of Incorporation of CytRx Corporation, filed with the Secretary of State of Delaware on July 2, 2008, July 8, 2011, May 15, 2012, October 31, 2017, and March 16, 2022. 4...",
"CytRx Corporation Relaunches as LadRx Corporation"
07/27/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
03/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress"
03/16/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF CYTRX CORPORATION CytRx Corporation , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: The Restated Certificate of Incorporation of the Corporation is hereby amended by deleting in its entirety the Fourth Article and by replacing it with the following: “FOURTH. The total number of shares of all classes of stock that the corporation shall have the authority to issue is Sixty-Three Million Two Hundred Twenty-Seven Thousand Two-Hundred Seventy-Three , of which Sixty-Two Million Three Hundred Ninety-Three Thousand Nine Hundred Forty shall be common stock, par value $0.001 per share , and Eight Hundred Thirty-Three Thousand ..."
03/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Believes Integration Will Bring Enhanced Efficiency and Simplicity to the Company’ s Structure Notes the Company Will Fold Centurion into CytRx"
02/17/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares Why did CytRx issue common and preferred shares to Armistice Capital? Following the announcement from Orphazyme in June 2021 that arimoclomol for Niemann-Pick Disease had not been granted FDA approval, the Board determined that a lack of action to raise additional capital to provide the Company financial flexibility at a critical time would have prevented them from complying with their fiduciary duties as directors of the Company. Since the Company did not have sufficient authorized common shares, CytRx entered into the Securities Purchase Agreement with Armistice Capital Master Fund, Ltd. , pursuant to which we issued and sold to Armistice, in a registered direct off..."
01/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Please Protect Our Assets and Help Your Company Avoid Running out of Cash by Voting FOR the Proposal at the Upcoming Special Meeting In July 2021, the Company entered into a securities purchase agreement with Armistice Capital Master Fund Ltd for aggregate gross proceeds of $10 million. This provided CytRx with much-needed working capital that helped us maintain stability as we efficiently managed our portfolio of licensing agreements and high-potential assets. Under the Armistice Capital agreement, the Company is obligated to pay – as partial liquidated damages and not as a penalty – monthly cash payments equal to the product of 2.0% multiplied by the aggregate subscription amount of $8,240,000 relating to the Series C Preferred Stock . Pursuant to the purchase agreement , monthly payment..."
01/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chairman of the Board of Directors",
"GENERAL RELEASE AND SEVERANCE AGREEMENT This General Release and Severance Agreement , dated as of January 3, 2022, is made and entered into by and between Steven Kriegsman and CytRx Corporation . For good and valuable consideration, receipt of which is hereby acknowledged, in order to effect a mutually satisfactory and amicable separation of employment from CytRx and to resolve and settle finally, fully and completely all matters and disputes that now or may exist between them, as set forth below, Executive and CytRx agree as follows: 1. Separation from Employment. Effective January 3, 2022 , Executive’ s employment with CytRx shall cease and he shall, as of the Separation Date, relinquish all positions, offices, and authority with CytRx. Notwithstanding the foregoing, Executive may choos...",
"CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer"
12/16/2021 8-K Quarterly results
12/15/2021 8-K Quarterly results
09/28/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
07/30/2021 8-K Quarterly results
07/15/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of the Designations, Powers, Preferences and Rights of Series C 10.00% Convertible Preferred Stock",
"Form of Preferred Investment Option",
"Opinion of Haynes and Boone, LLP",
"Form of Securities Purchase Agreement, by and between the Company and the purchaser thereto",
"Form of Registration Rights Agreement, by and between the Company and the purchaser thereto",
"CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor"
05/27/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
11/17/2020 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Amended and Restated Certificate of Designation of Series B Junior Participating Preferred Stock of CytRx Corporation",
"Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020",
"Amended and Restated Rights Agreement, by and between CytRx Corporation and American Stock Transfer & Trust Company, as Rights Agent"
09/03/2020 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "*** About CytRx Corporation CytRx Corporation is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’ s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’ s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including amyotrophic lateral sclerosis , Niemann-Pick disease Type C , Gaucher disease and sporadic Inclusion Body Myositis . Learn more at www.cytrx.com . 1 Forward-Looking Statements This press release contains forward-loo..."
08/24/2020 8-K Quarterly results
07/16/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
05/27/2020 8-K/A Submission of Matters to a Vote of Security Holders
03/11/2020 8-K Quarterly results
01/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2019 8-K Quarterly results
11/15/2019 8-K Quarterly results
08/29/2019 8-K Other Events
08/01/2019 8-K Other Events
06/26/2019 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter of BDO USA, LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy